SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Sanofi (SNYNF) trades at a trailing P/E of 14.8, forward P/E of 11.4. Trailing earnings yield is 6.75%, forward earnings yield 8.80%. PEG 0.33 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (85/100, Pass) — P/E is below market average (14.8); PEG ≤ 1.0 — Peter Lynch undervalued (0.33); earnings yield beats bond yields (6.75%).
- Forward P/E 11.4 (down from trailing 14.8) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.33 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 6.75% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 8.80% as earnings recover.
Overall SharesGrow Score: 68/100 with 5/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
85/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
83/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — SNYNF
Valuation Multiples
P/E (TTM)14.8
Forward P/E11.4
PEG Ratio0.33
Forward PEG0.38
P/B Ratio0.00
P/S Ratio2.65
EV/EBITDA0.0
Per Share Data
EPS (TTM)$6.40
Forward EPS (Est.)$8.34
Book Value / Share$0.00
Revenue / Share$35.73
FCF / Share$0.00
Yields & Fair Value
Earnings Yield6.75%
Forward Earnings Yield8.80%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$3.63 |
$34.71B |
$4.71B |
13.6% |
| 2017 |
$6.64 |
$36.2B |
$8.43B |
23.3% |
| 2018 |
$3.43 |
$35.68B |
$4.31B |
12.1% |
| 2019 |
$2.31 |
$37.63B |
$2.81B |
7.5% |
| 2020 |
$9.76 |
$37.37B |
$12.29B |
32.9% |
| 2021 |
$4.95 |
$39.18B |
$6.22B |
15.9% |
| 2022 |
$6.66 |
$45.39B |
$8.37B |
18.4% |
| 2023 |
$4.30 |
$46.44B |
$5.4B |
11.6% |
| 2024 |
$4.43 |
$44.29B |
$5.56B |
12.6% |
| 2025 |
$6.40 |
$43.61B |
$7.81B |
17.9% |
